Safety Study of Fenofibrate During Pregnancy

NCT05883865 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 250

Last updated 2023-06-01

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety of fenofibrate in severe hypertriglyceridemia pregnant women.

Conditions

  • Severe Hypertriglyceridemia During Pregnancy

Interventions

DRUG

Fenofibrate

Fenofibrate is orally administrated daily with food for at least 1 week during pregnancy

Sponsors & Collaborators

  • First People's Hospital of Hangzhou

    lead OTHER

Eligibility

Min Age
20 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-01
Primary Completion
2024-06-01
Completion
2025-12-01
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05883865 on ClinicalTrials.gov